cancer immunotherapy - our gene therapy science to treat cancer we develop a gene transfer strategy into autologous hematopoietic stem/progenitor cells (hspcs) to target interferon-α expression to tumor-infiltrating monocytes/macrophages. an hiv-derived and genetically disabled viral vector - lentivirus - delivers the gene into the hspcs. interferon is a protein usually produced by the body in response to infections that also exhibits a powerful anti-tumor activity. however, the clinical use of interferon as a drug has been limited by its high toxicity. thanks to our innovative therapy, using a combination of transcriptional and microrna-mediated control, tumor-infiltrating monocytes/macrophages become capable to selectively express interferon limited to the tumor area, thus reducing its toxicity. based on these mechanisms, a population of tumor-infiltrating monocytes/macrophages, tie2-expressing monocytes (tems), are armed with a specific drug.
Company profile
Ticker
GNTA
Exchange
Website
Employees
Incorporated
Location
Industry (SIC)
Former names
Genenta Science S.r.l.
SEC CIK
GNTA stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
3 May 24
6-K
Current report (foreign)
26 Apr 24
424B5
Prospectus supplement for primary offering
26 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Notice of Call of the Ordinary and Extraordinary Shareholders’ Meeting
2 Apr 24
20-F/A
2023 FY
Annual report (foreign) (amended)
1 Apr 24
S-8
Registration of securities for employees
29 Mar 24
20-F
2023 FY
Annual report (foreign)
29 Mar 24
6-K
Current report (foreign)
20 Oct 23
6-K
Current report (foreign)
14 Jun 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
12.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 3 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 297.47 mm |
Total shares | 2.36 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ospedale San Raffaele | 1.90 mm | $20.79 mm |
Bank Julius Baer & Co. Ltd, Zurich | 412.55 k | $2.46 mm |
Algebris (UK) | 45.00 k | $267.14 mm |
UBS UBS Group AG - Registered Shares | 700.00 | $4.13 mm |
MS Morgan Stanley | 500.00 | $2.95 mm |
Proequities | 0.00 | $0.00 |